Fortrea Holdings Past Earnings Performance
Past criteria checks 0/6
Fortrea Holdings has been growing earnings at an average annual rate of 2.2%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 0.6% per year.
Key information
2.2%
Earnings growth rate
-114.2%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -0.6% |
| Return on equity | -14.4% |
| Net Margin | -7.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
There Is A Reason Fortrea Holdings Inc.'s (NASDAQ:FTRE) Price Is Undemanding
Nov 21
Would Fortrea Holdings (NASDAQ:FTRE) Be Better Off With Less Debt?
Aug 16Fortrea Holdings: Still Many Question Marks On This CRO Play
May 12Fortrea: High Risk And Low Upside Potential
Feb 13Fortrea Holdings Inc.'s (NASDAQ:FTRE) Low P/S No Reason For Excitement
Feb 08Fortrea Holdings' (NASDAQ:FTRE) Soft Earnings Are Actually Better Than They Appear
Nov 23Revenue & Expenses Breakdown
How Fortrea Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,976 | -218 | 428 | 0 |
| 30 Jun 24 | 3,015 | -215 | 398 | 0 |
| 31 Mar 24 | 3,077 | -91 | 340 | 0 |
| 31 Dec 23 | 3,109 | -3 | 337 | 0 |
| 30 Sep 23 | 2,895 | 50 | 385 | 0 |
| 30 Jun 23 | 2,943 | 127 | 349 | 0 |
| 31 Mar 23 | 3,011 | 168 | 322 | 0 |
| 31 Dec 22 | 3,096 | 193 | 280 | 0 |
| 31 Dec 21 | 3,058 | 98 | 303 | 0 |
| 31 Dec 20 | 2,580 | -359 | 268 | 0 |
Quality Earnings: FTRE is currently unprofitable.
Growing Profit Margin: FTRE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FTRE is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare FTRE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FTRE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: FTRE has a negative Return on Equity (-14.4%), as it is currently unprofitable.